Form 4: BioMarin CTO Plans Future Stock Sale for Tax Obligations

BioMarin Pharmaceutical's EVP, Chief Technical Officer, Charles Greg Guyer, filed a Form 4 detailing a future disposition of 1,693 shares of common stock on March 17, 2026, to cover tax liabilities under a 10b5-1 plan.

Summary

• Charles Greg Guyer, EVP, Chief Technical Officer of BioMarin Pharmaceutical Inc. (BMRN), reported a planned disposition of common stock.
• The transaction, scheduled for March 17, 2026, involves the disposal of 1,693 shares of common stock at a price of $56.05 per share.
• This disposition is marked with transaction code 'F', indicating it is for the payment of tax liability by withholding securities.
• Following this planned transaction, Mr. Guyer will beneficially own 84,140 shares of BioMarin Pharmaceutical Inc. common stock.
• The transaction is being made pursuant to a Rule 10b5-1 trading plan, as indicated by the checked box on the filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine, pre-planned insider sale for tax purposes, which typically has no bearing on the company's operational performance or future prospects.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those marked with code 'F' for tax withholding and executed under a Rule 10b5-1 plan, are common and generally not indicative of a change in company fundamentals or management's long-term outlook. These are typically pre-scheduled events for personal financial planning.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction for tax withholding purposes under a 10b5-1 plan and does not provide new information that would alter the fundamental investment thesis for BioMarin Pharmaceutical Inc.

Keywords

BMRN, BioMarin Pharmaceutical, Form 4, Insider Transaction, Stock Sale, Executive Compensation, Charles Greg Guyer, 10b5-1 Plan